NCT01610388View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 13, 2011

Primary Completion Date

January 26, 2012

Study Completion Date

January 26, 2012

Conditions
Infections, Bacterial
Interventions
DRUG

500mg IV GSK1322322/placebo

500mg IV

DRUG

1000mg oral GSK1322322/placebo

1000mg oral

DRUG

1000mg IV GSK1322322/placebo

1000mg IV

DRUG

1500mg oral GSK1322322/placebo dose

1500mg oral

DRUG

1500mg IV GSK1322322/placebo

1500mg IV

DRUG

2000mg IV GSK1322322J/placebo

2000mg IV

DRUG

3000mg IV GSK1322322J/placebo

3000mg IV

DRUG

1000mg IV GSK1322322J/placebo

1000mg IV

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01610388 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects | Biotech Hunter | Biotech Hunter